Sridhar SS - Search Results

1

Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.

Feld R, Sridhar SS, Shepherd FA, Mackay JA, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Feld R, et al. Among authors: sridhar ss. J Thorac Oncol. 2006 May;1(4):367-76. J Thorac Oncol. 2006. PMID: 17409886 Free article. Review.

2

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.

Sridhar SS, Seymour L, Shepherd FA. Sridhar SS, et al. Lancet Oncol. 2003 Jul;4(7):397-406. doi: 10.1016/s1470-2045(03)01137-9. Lancet Oncol. 2003. PMID: 12850190 Review.

3

Angiogenesis inhibitors under study for the treatment of lung cancer.

Shepherd FA, Sridhar SS. Shepherd FA, et al. Among authors: sridhar ss. Lung Cancer. 2003 Aug;41 Suppl 1:S63-72. doi: 10.1016/s0169-5002(03)00144-2. Lung Cancer. 2003. PMID: 12867064 Review.

4

Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer.

Sridhar SS, Shepherd FA. Sridhar SS, et al. Lung Cancer. 2003 Dec;42 Suppl 1:S81-91. doi: 10.1016/s0169-5002(03)00308-8. Lung Cancer. 2003. PMID: 14611919 Review.

5

Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients.

Kim S, Tannock I, Sridhar S, Seki J, Bordeleau L. Kim S, et al. J Oncol Pharm Pract. 2012 Jun;18(2):311-5. doi: 10.1177/1078155211429384. Epub 2012 Jan 4. J Oncol Pharm Pract. 2012. PMID: 22217649 Review.

6

Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer.

Emmenegger U, Booth CM, Berry S, Sridhar SS, Winquist E, Bandali N, Chow A, Lee C, Xu P, Man S, Kerbel RS, Ko YJ. Emmenegger U, et al. Among authors: sridhar ss. Oncologist. 2015 Dec;20(12):1351-2. doi: 10.1634/theoncologist.2015-0220. Epub 2015 Nov 5. Oncologist. 2015. PMID: 26542984 Free PMC article. Clinical Trial.

7

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.

Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D, Pan CX, Kim JJ, Aragon-Ching JB, Quinn DI, Vogelzang NJ, Tang S, Zhang H, Cavanaugh CT, Gao L, Kauh JS, Walgren RA, Chi KN. Petrylak DP, et al. Among authors: sridhar ss. J Clin Oncol. 2016 May 1;34(13):1500-9. doi: 10.1200/JCO.2015.65.0218. Epub 2016 Feb 29. J Clin Oncol. 2016. PMID: 26926681 Clinical Trial.

8

Evolving Treatment of Advanced Urothelial Cancer.

Sridhar SS. Sridhar SS. J Oncol Pract. 2017 May;13(5):309-315. doi: 10.1200/JOP.2017.022137. J Oncol Pract. 2017. PMID: 28489981 Review.

9

Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.

O'Donnell PH, Arkenau HT, Sridhar SS, Ong M, Drakaki A, Spira AI, Zhang J, Gordon MS, Degboe AN, Gupta AK, Mukhopadhyay P, Huang W, Abdullah SE, Angra N, Roskos LK, Guo X, Friedlander T. O'Donnell PH, et al. Among authors: sridhar ss. Cancer. 2020 Jan 15;126(2):432-443. doi: 10.1002/cncr.32532. Epub 2019 Oct 3. Cancer. 2020. PMID: 31581306 Free article. Clinical Trial.

10

Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials.

Wong SE, Quinn DI, Bjarnason GA, North SA, Sridhar SS. Wong SE, et al. Among authors: sridhar ss. Am J Clin Oncol. 2020 Aug;43(8):559-566. doi: 10.1097/COC.0000000000000705. Am J Clin Oncol. 2020. PMID: 32398404 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

215 results

Search Page

Filters